Improving the fate of severely infected patients: the promise of anti-toxin treatments and superiority trials

Expert Review of Anti-Infective Therapy

Volumn 15, Issue 11, 2017, Pages 973-975

  Azeredo da Silveira, Samareh ^a   Perez, Antonio ^a  

^a Combioxin SA ^*  (Switzerland)

Author keywords

anti toxin agents; non antibiotic; non inferiority; Severe infections; superiority

Indexed keywords

ANTIBIOTIC AGENT; ANTITOXIN; ASN 100; BACTERIAL TOXIN; BEZLOTOXUMAB; CAL 02; MEDI 3902; MONOCLONAL ANTIBODY; SALVECIN; SUVRATOXUMAB; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

BACTERICIDAL ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TARGETING; EDITORIAL; HUMAN; INFECTION; MEDICAL RESEARCH; PEPTOCLOSTRIDIUM DIFFICILE; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; TYPE III SECRETION SYSTEM; ANTAGONISTS AND INHIBITORS; BACTERIAL INFECTION; CLINICAL TRIAL (TOPIC); METHODOLOGY; PATHOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIAL TOXINS; CLINICAL TRIALS AS TOPIC; HUMANS; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX;

EID: 85033685742     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2017.1400908     Document Type: Editorial

References (18)

1. Mullard A., FDA approves antitoxin antibody. Nat Rev Drug Discov. 2016;15:811.
2. Los FC, Randis TM, Aroian RV, et al. Role of pore-forming toxins in bacterial infectious diseases. Microbiol Mol Biol Rev. 2013;77:173–207.
3. Otto M. Staphylococcus aureus toxins. Curr Opin Microbiol. 2014;17:32–37.
4. Berube BJ, Rangel SM, Hauser AR. Pseudomonas aeruginosa: breaking down barriers. Curr Genet. 2016;62:109–113.
5. Hirst RA, Kadioglu A, O’Callaghan C, et al. The role of pneumolysin in pneumococcal pneumonia and meningitis. Clin Exp Immunol. 2004;138:195–201.
6. Orihuela CJ, Gao G, Francis KP, et al. Tissue-specific contributions of pneumococcal virulence factors to pathogenesis. J Infect Dis. 2004;190:1661–1669.
7. Torres A. Community-acquired pneumonia: changing paradigms about mortality. Community Acquired Infection. 2017;1:1.
8. Henry BD, Neill DR, Becker KA, et al. Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. Nat Biotechnol. 2015;33:81–88.
9. Hua L, Hilliard JJ, Shi Y, et al. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother. 2014;58:1108–1117.
10. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673–1681.
11. Corey GR, Wilcox MH, Talbot GH, et al. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65 Suppl 4:iv41–51.
12. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005;41 Suppl 5:S341–53.
13. Friedland HD, O’Neal T, Biek D, et al. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2012;56:2231–2236.
14. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008;46:1683–1693.
15. Government Accountability Office (GAO). New drug approval: FDA’s consideration of evidence from certain clinical trials. GAO-10-798(2010).
16. Timsit JF, De Kraker MEA, Sommer H, et al. Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE’s STAT-Net. Intensive Care Med. 2017;43:1002–1012.
17. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases. Guidance Ind. 2017.
18. Doshi P, Hur P, Jones M, et al. Informed consent to study purpose in randomized clinical trials of antibiotics, 1991 through 2011. JAMA Intern Med. 2017;177(10):1-8.